Sarcomas/TGCT | Specialty

The OncLive Sarcomas/TGCT condition center page is a comprehensive resource for clinical news and expert insights on tenosynovial giant cell tumor (TGCT), soft tissue sarcoma, gastrointestinal stromal tumor, Ewing sarcoma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in sarcomas and TGCT.

Surgery Following Imatinib Boosts Survival for GIST Patients

January 23rd 2013

A retrospective analysis of the potential benefits of surgery following treatment with imatinib (Gleevec) suggests a clear benefit in both OS and PFS in patients with metastatic or recurrent GIST when compared with those who received imatinib therapy alone.

ï»¿Evolution of Targeted Therapy: GIST Experience Points the Way to Defining Third-Line Treatment

November 19th 2012

Targeted antineoplastic therapy based on the presence of a well-defined molecular target should be recognized as a standard-of-care approach in an increasing number of clinical settings.

In Refractory GIST, Regorafenib Delays Disease Progression Across All Subgroups

October 3rd 2012

Regorafenib significantly delays disease progression in virtually all subgroups of patients with GIST in the second-line setting, and may even confer benefits when continued after progression.

No Survival Advantage for Ifosfamide Added to Doxorubicin in Advanced Soft Tissue Sarcoma

October 2nd 2012

The addition of ifosfamide to doxorubicin in the treatment of advanced soft tissue sarcomas delayed disease progression but did not improve survival.

Dr. Demetri Describes the MOA of Regorafenib in GIST

September 10th 2012

Dr. George Demetri, from the Dana-Farber Cancer Institute, Describes the Mechanism of Action of Regorafenib in Gastrointestinal Stromal Tumors.

Dr. Demetri Explains the Side Effects of Regorafenib

June 20th 2012

Dr. George Demetri, from Dana-Farber Cancer Institute, Explains the Side Effects Associated With Regorafenib.

Pazopanib Receives FDA Approval for Treatment of Soft Tissue Sarcoma

April 27th 2012

The FDA has approved pazopanib for the treatment of patients with advanced soft tissue sarcoma who have previously received chemotherapy.

Immunotherapy and Radiation Provide Good Tumor Response in Sarcoma Patients

April 16th 2012

A combination of immunotherapy and fractionated external-beam radiation therapy provided tumor-specific immune responses in patients with soft-tissue sarcoma.

ODAC Recommends Pazopanib But Not Ridaforolimus for Sarcoma

March 21st 2012

ODAC has recommended the approval of pazopanib but ruled against the agent ridaforolimus to treat sarcoma.

Pazopanib Shows 3-Fold Improvement in Progression-Free Survival

August 4th 2011

Patients with anthracycline-treated sarcomas had a 3-fold improvement in PFS with antiangiogenic agent pazopanib versus placebo.

Dr. Joensuu Discusses Resistance to Imatinib in GIST

July 5th 2011

Dr. Heikki Joensuu from the Helsinki University Central Hospital Discusses Resistance to Imatinib in GIST

Dr. Kris Discusses the Imatinib GIST Clinical Trial

June 20th 2011

Dr. Kris From Memorial Sloan-Kettering Cancer Center Discusses the Imatinib GIST Clinical Trial

Dr. Joensuu Discusses the Progress of GIST Treatments

June 8th 2011

Dr. Heikki Joensuu from the Helsinki University Central Hospital Discusses the Progress of gastrointestinal stromal tumors (GIST) Treatments

Modified Herpes Virus to Be Tested in Sarcoma Patients

March 9th 2011

The FDA has awarded a $600,000 grant for a phase I clinical trial of a genetically reprogrammed herpes simplex virus in young cancer patients with relapsed non-central nervous system (CNS) solid tumors such as sarcomas and neuroblastomas.

Net Guides: Childhood Tumors

March 6th 2011

Useful Online Resources and Clinical Trials for Childhood-Tumors